The Syntegon Group has achieved its best result to date in the 2024 financial year. Driven by a new corporate strategy, which has been in place since the change in CEO at the end of 2023, the company was able to significantly increase incoming orders and sales, according to Waiblingen.
Compared to the previous year, incoming orders grew by 11 per cent to 1.8 billion euros. Sales increased by 7 per cent to 1.6 billion euros. The operating earnings indicator EBITDA improved by 15 per cent to 222 million euros, which corresponds to a margin of 14 per cent. Targeted management of working capital helped to strengthen cash flow.
Pharmaceuticals as a growth driver
The pharmaceutical business in particular recorded strong momentum in 2024, with a 17 per cent increase in incoming orders and an 11 per cent rise in sales. This division accounted for 58 per cent of the total order volume. According to the company, the Pharma Liquid division, which focuses on aseptic filling of medications for treating obesity, among other things, proved to be key to order growth.
„In 2024, we have opened a new chapter of accelerated growth and increased value creation. We rely on the unique talent of our Syntegon employees, and our customers value both our lifecycle service and our end-to-end solutions approach. Thanks to our new strategic direction, we are ideally positioned to capitalise on strong long-term growth trends, particularly in the pharmaceutical and biotechnology sectors.“
Torsten Türling, CEO of Syntegon
Business with the food industry accounted for 42 per cent of the total volume. It achieved order growth of 4 per cent and an increase in turnover of 2 per cent. Business with horizontal packaging machines in Switzerland in particular contributed significantly to the result. The lower-margin food liquids business was sold as part of the strategic reorganisation.
Portfolio expansion and sustainability
An important strategic step was the acquisition of the Telstar Group Telstar specialises in freeze-drying technologies for pharmaceutical and biotech applications. The acquisition expands Syntegon's offering in the area of complete aseptic solutions, for example for vaccines or plasma products.
In the area of sustainability, Syntegon has had its climate targets validated by the Science Based Targets initiative. The aim is to reduce direct and indirect emissions (Scope 1 and 2) by 50 per cent and upstream and downstream emissions (Scope 3) by 25 per cent by 2030. In April 2025, the company was awarded a platinum rating by Ecovadis.
Outlook 2025
According to Syntegon, it expects further growth in the current 2025 financial year. The basis for this is a high order backlog, positive market dynamics, particularly in the pharmaceutical sector, and the increasing importance of the high-margin service business. Operational efficiency improvements should also contribute to margin development.
Source: Syntegon
